Nuclear Imaging of Glucose Metabolism: Beyond 18F-FDG. (26th March 2019)

• Record Type: Journal Article
• Authors: Feng, Han; Wang, Xiaobo; Chen, Jian; Cui, Jing; Gao, Tang; Gao, Yongju; Zeng, Wenbin
• Other Names: Hong Hao Academic Editor.
• Is Part Of: Contrast media & molecular imaging. Volume 2019(2019)
• Publication Date: 2019-03-26
• Subjects: Diagnostic imaging -- Periodicals; Magnetic resonance imaging -- Periodicals; Contrast media (Diagnostic imaging) -- Periodicals; Contrast Media -- Periodicals; Diagnostic Imaging -- Periodicals; Substances de contraste -- Périodiques; Diagnostics moléculaires -- Périodiques; Imagerie médicale; Substance de contraste; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.0754
• DOI: 10.1155/2019/7954854
• Languages: English
• ISSNs: 1555-4309

Abstract

Abstract : Glucose homeostasis plays a key role in numerous fundamental aspects of life, and its dysregulation is associated with many important diseases such as cancer. The atypical glucose metabolic phenomenon, known as the Warburg effect, has been recognized as a hallmark of cancer and serves as a promising target for tumor specific imaging. At present, 2-deoxy-2-[ 18 F]fluoro-glucose ( 18 F-FDG)-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for this purpose. The powerful impact of 18 F-FDG has prompted intensive research efforts into other glucose-based radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging. Currently, glucose and its analogues have been labeled with various radionuclides such as 99m Tc, 111 In, 18 F, 68 Ga, and 64 Cu and have been successfully investigated for tumor metabolic imaging in many preclinical studies. Moreover, 99m Tc-ECDG has advanced into its early clinical trials and brings a new era of tumor imaging beyond 18 F-FDG. In this review, preclinical and early clinical development of glucose-based radiopharmaceuticals for tumor metabolic imaging will be summarized.